Detalles de la búsqueda
1.
Cost-effectiveness analysis of atezolizumab plus bevacizumab compared with sorafenib as first-line treatment in advanced hepatocellular carcinoma in Singapore.
Expert Rev Pharmacoecon Outcomes Res
; 24(5): 631-641, 2024 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-38776431
2.
Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore.
J Gynecol Oncol
; 32(2): e27, 2021 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-33559410
Resultados
1 -
2
de 2
1
Próxima >
>>